Can the Migraine Drug Galcanezumab Also Reduce Inflammatory Markers? | Research

The takeaway

Galcanezumab, a CGRP-blocking migraine antibody, may also modulate inflammatory cytokine levels, suggesting anti-CGRP therapy has broader anti-inflammatory effects beyond just blocking pain pathways.

Cytokine modulation observed
Galcanezumab altered inflammatory marker profiles beyond CGRP blockade alone

What the researchers found

Galcanezumab treatment was associated with changes in inflammatory cytokine profiles in migraine patients, suggesting the drug may have anti-inflammatory effects beyond CGRP blockade.

Why it matters

Not all migraine patients respond to CGRP-targeted drugs. If galcanezumab also reduces inflammation, it could help identify which patients will benefit most and potentially expand its therapeutic applications.

How the study worked

Single-centre exploratory clinical study measuring cytokine profiles in episodic and chronic migraine patients before and during galcanezumab treatment.

What this study cannot tell us

Exploratory single-centre design limits generalizability; likely small sample size; correlation between cytokine changes and clinical improvement not definitively established.

How to read the evidence

Exploratory single-centre study — generates hypotheses about anti-inflammatory mechanisms but requires larger confirmatory trials.

When this study was published

Published in 2026, reflecting the latest research into CGRP antibody mechanisms of action.

The bigger picture

This connects CGRP biology to broader neuroinflammation in migraine, potentially explaining treatment response variability and opening doors to combination anti-inflammatory approaches for resistant migraine.

Questions still open

Do patients with higher baseline inflammation respond better to galcanezumab?
Could combining galcanezumab with anti-inflammatory agents improve outcomes for non-responders?

Common questions

What is galcanezumab and how does it treat migraines?

Galcanezumab is a monthly injectable antibody that blocks CGRP, a peptide that triggers migraine attacks. It's sold as Emgality and reduces migraine frequency in many patients.

Why might anti-inflammatory effects matter for migraine treatment?

Not all migraines are driven purely by CGRP. If galcanezumab also dampens neuroinflammation, it could explain why it helps some patients and might lead to better treatments for those who don't respond to CGRP blockade alone.

Read the original research

Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study.

Journal of neurology, 273(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Ceccardi, Giulia; Rao, Renata; Schiano di Cola, Francesca; Fiducia, Beatrice; Tolassi, Chiara; Quaresima, Virginia; Mattioli, Irene; Eshja, Klaudia; Cresta, Elena; Gipponi, Stefano; Pilotto, Andrea; Padovani, Alessandro. (2026). Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study.. Journal of neurology, 273(2). https://doi.org/10.1007/s00415-026-13706-3